A daytime anxiolytic for the cardiac patient: what the evidence says about temgicoluril
УДК: УДК 616.127-005.8-06:616.89-008.441-085.214
- 1. Emdin C.A., Odutayo A., Wong C.X. et al. (2016) Meta-analysis of anxiety as a risk factor for cardiovascular disease. Am. J. Cardiol., 118(4): 511–519. doi: 10.1016/j.amjcard.2016.05.041.
- 2. Vogelzangs N., Beekman A.T.F., Milaneschi Y. et al. (2010) Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. J. Clin. Endocrinol. Metab., 95(11): 4959–4964. doi: 10.1210/jc.2010-0192.
- 3. Larsson S.C., Lee W.H., Burgess S., Allara E. (2021) Plasma cortisol and risk of atrial fibrillation: a Mendelian randomization study. J. Clin. Endocrinol. Metab., 106(7): e2521–e2526. doi: 10.1210/clinem/dgab219.
- 4. McEwen B.S. (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev., 87(3): 873–904. doi: 10.1152/physrev.00041.2006.
- 5. Chrousos G.P. (2009) Stress and disorders of the stress system. Nat. Rev. Endocrinol., 5(7): 374–381. doi: 10.1038/nrendo.2009.106.
- 6. Whitworth J.A., Williamson P.M., Mangos G., Kelly J.J. (2005) Cardiovascular consequences of cortisol excess. Vasc. Health Risk Manag., 1(4): 291–299. doi: 10.2147/vhrm.1.4.291.
- 7. Yang S., Zhang L. (2004) Glucocorticoids and vascular reactivity. Curr. Vasc. Pharmacol., 2(1): 1–12. doi: 10.2174/1570161043476483.
- 8. Tsai S.Y., Hsu J.Y., Lin C.H. et al. (2024) Association of stress hormones and the risk of cardiovascular diseases systematic review and meta-analysis. Int. J. Cardiol. Cardiovasc. Risk Prev., 23: 200305. doi: 10.1016/j.ijcrp.2024.200305.
- 9. Obeagu E.I. (2025) Stress-induced hemostasis: mechanisms and implications for health. Ann. Med. Surg. (Lond.), 87(6): 3300–3309. doi: 10.1097/MS9.0000000000003012.
- 10. Cohen S., Janicki-Deverts D., Doyle W.J. et al. (2012) Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc. Natl. Acad. Sci. USA, 109(16): 5995–5999. doi: 10.1073/pnas.1118355109.
- 11. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. (2009) Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci., 10(6): 434–445. doi: 10.1038/nrn2639.
- 12. Hirotsu C., Tufik S., Andersen M.L. (2015) Interactions between sleep, stress, and metabolism: from physiological to pathological conditions. Sleep Sci., 8(3): 143–152. doi: 10.1016/j.slsci.2015.09.002.
- 13. Konturek P.C., Brzozowski T., Konturek S.J. (2011) Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J. Physiol. Pharmacol., 62(6): 591–599.
- 14. Liu Z. (2025) The bidirectional relationship between FGIDs and anxiety: pathophysiological mechanisms and new therapeutic strategies. Actas Esp. Psiquiatr., 53(4): 914–926. doi: 10.62641/aep.v53i4.1852.
- 15. Choi E.H., Brown B.E., Crumrine D. et al. (2005) Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J. Invest. Dermatol., 124(3): 587–595. doi: 10.1111/j.0022-202X.2005.23589.x.
- 16. Arck P.C., Slominski A., Theoharides T.C. et al. (2006) Neuroimmunology of stress: skin takes center stage. J. Invest. Dermatol., 126(8): 1697–1704. doi: 10.1038/sj.jid.5700104.
- 17. Zhang H., Wang M., Zhao X. et al. (2024) Role of stress in skin diseases: a neuroendocrine-immune interaction view. Brain Behav. Immun., 116: 286–302. doi: 10.1016/j.bbi.2023.12.005.
- 18. Vaccarino V., Bremner J.D. (2024) Stress and cardiovascular disease: an update. Nat. Rev. Cardiol., 21(9): 603–616. doi: 10.1038/s41569-024-01024-y.
- 19. Manenschijn L., Schaap L., van Schoor N.M. et al. (2013) High long-term cortisol levels, measured in scalp hair, are associated with a history of cardiovascular disease. J. Clin. Endocrinol. Metab., 98(5): 2078–2083. doi: 10.1210/jc.2012-3663.
- 20. Abakumova T.R., Aleksandrova E.G., Ziganshina L.Ye. (2026) Temgikoluril (Mebikar®): aktualnost i perspektivy primeneniya (k 90-letiyu professora Iriny Evgenyevny Zimakovoy). Kazan. med. zhurn., 107(1): 77–85. doi: 10.17816/KMJ692937.
- 21. Seredyuk L., Vakalyuk I. (2020) Effectiveness of treatment with mebicar in patients with permanent atrial fibrillation. EUREKA Health Sci., (5): 41–50. doi: 10.21303/2504-5679.2020.001385.
- 22. Інструкція для медичного застосування лікарського засобу Адаптол® (темгіколурил), таблетки 500 мг; капсули 300 мг. (2025) Дата останнього перегляду: 27.06.2025. Державний реєстр лікарських засобів України.
- 23. Kim C.Y., Kim Y.G., Sin S.J. et al. (2018) Preventive effect of mebicar and ginsenoside Rg1 on neurobehavioral and immunological disruptions caused by intermittent unpredictable stress in mice. Neuroimmunomodulation, 25(1): 49–58. doi: 10.1159/000489634.
- 24. Shilina N.N., Statsenko M.E., Sporova O.E., Lempert B.A. (2013) Effektivnost adaptola i vozmozhnost ego differentsirovannogo primeneniya u bolnykh s trevozhnymi rasstroystvami v postinfarktnom periode. Terapevt. arkh., 85(9): 29–34.
- 25. Mkrtchyan V.R., Kozhokova L.Z. (2012) Adaptol® — grani vozmozhnogo. Лікар. справа, (5): 125–133. doi: 10.31640/LS-2012-5-15.
- 26. Taube M., Dansone G., Troshina Y. (2025) Efficacy of Adaptol® 500 mg tablets in patients with anxiety and somatic symptoms of anxiety disorder: a noninterventional study. J. Clin. Med., 14(22): 7972. doi: 10.3390/jcm14227972.
- 27. Kozhokova L.Z., Mkrtchyan V.R. (2014) Vliyanie adaptola na lipidnyy obmen u bolnykh stenokardiey I–III funktsionalnogo klassa. Kardiologiya i serdechno-sosudistaya khirurgiya, 7(1): 33–37.
- 28. Serediuk L., Vakalyuk I., Tsimbalyuk U., Bila L. (2019) Effectiveness of treating patients with stable ischemic heart disease and co-existent paroxysmal atrial fibrillation with mebicar. Arch. Clin. Med., 25(2): 24–29. doi: 10.21802/acm.2019.2.2.
- 29. Tsurko S., Tyabut T., Baykova I., Marchenko-Tyabut D. (2012) Use of Adaptol® in patients with acute myocardial infarction. Eurasian J. Healthc., 2(2): 43–46.
- 30. Kamburg R.A., Valimukhametova D.A. (1984) Effektivnost mebikara pri khronicheskoy ishemicheskoy bolezni serdtsa. Kazan. med. zhurn., 65(6): 424–426. doi: 10.17816/kazmj89505.
- 31. Shcherbatenko L.A., Tagirova T.S., Kamburg R.A. (1986) Effektivnost mebikara v lechenii stenokardii napryazheniya. Kazan. med. zhurn., 67(5): 321–325. doi: 10.17816/kazmj70577.
- 32. Dotsenko N.Ya., Boev S.S., Shekhunova I.A., Dedova V.O. (2014) Parallelnaya farmakologicheskaya korrektsiya disfunktsii miokarda, kognitivnykh i psikhopatologicheskikh rasstroystv u bolnykh s khronicheskoy serdechnoy nedostatochnostyu. Лікар. справа, (1–2): 27–35. doi: 10.31640/LS-2014-(1-2)-04.
- 33. Tsurinova E.A., Treshkur T.V., Ilina D.Yu. (2013) Sluchay effektivnogo lecheniya psikhogennoy zheludochkovoy aritmii anksiolitikom adaptolom. Terapevt. arkh., 85(3): 94–97.
- 34. Zimakova I.E., Salikhova R.R., Tagirova T.S. et al. (1996) Effect of the tranquilizer mebicar on lipid metabolism and lipid peroxidation on the model of hypokinesia in rats. Bull. Exp. Biol. Med., 121(5): 484–486. doi: 10.1007/BF02446944.
- 35. Lapshina L.A., Kravchun P.G., Shevchenko O.S. (2008) Korrektsiya adaptolom psikhopatologicheskikh proyavleniy i oksidativnogo stressa u bolnykh, perenesshikh infarkt miokarda. Vracheb. praktika, (1): 23–30.
- 36. Levin O.S. (2024) Izuchenie effektivnosti i vliyaniya na kachestvo zhizni patsientov s subklinicheskim i klinicheski vyrazhennym trevozhnym rasstroystvom mobilnogo prilozheniya v sochetanii s terapiey preparatom Adaptol. Zhurn. nevrol. psikhiatr. im. S.S. Korsakova, 124(7): 98–105. doi: 10.17116/jnevro202412407198.
- 37. Barantsevich E.R., Posokhina O.V. (2011) Kliniko-neyrofiziologicheskoe issledovanie effektivnosti adaptola pri distsirkulyatornoy entsefalopatii. Zhurn. nevrol. psikhiatr. im. S.S. Korsakova, 111(9, vyp. 2): 68–72.
- 38. Zhivolupov S.A., Samartsev I.N., Marchenko A.A., Pulyatkina O.V. (2012) Prognosticheskoe znachenie soderzhaniya v krovi neyrotroficheskogo faktora mozga (BDNF) pri terapii nekotorykh funktsionalnykh i organicheskikh zabolevaniy nervnoy sistemy s primeneniem adaptola. Zhurn. nevrol. psikhiatr. im. S.S. Korsakova, 112(4): 37–41.
- 39. Seredyuk L. (2019) Effectiveness of treatment with mebicar in patients with permanent atrial fibrillation, which arose on the background of anxiety and depression. Pol. J. Appl. Sci., 5(2): 5–10. doi: 10.34668/PJAS.1019.5.2.01.
- 40. Сидорова Н.М. (2021) Ліки від страху. Аналітичний огляд літератури. Сучасні аспекти військової медицини, 28(2): 173–188. doi: 10.32751/2310-4910-2021-28-2-15.